Recent trading in Ocular Therapeutix (OCUL) has drawn attention, with the stock declining over the past week while remaining higher over the past month and over the past year.

Taking a step back, the stock’s recent pullback sits against a mixed backdrop, with the share price down year to date but a 1 year total shareholder return of 30.86%, suggesting earlier optimism has cooled near the current US$9.16 level.

If you are comparing Ocular Therapeutix with other eye care and biotech opportunities that use AI in healthcare, it can be useful to widen your watchlist with 33 healthcare AI stocks.

So with Ocular Therapeutix shares pulling back year to date yet still showing a 1 year total return of 30.86% and trading at US$9.16, are you looking at an undervalued growth story or a stock where future growth is already priced in?

Most Popular Narrative: 64.8% Undervalued

Compared with the last close at $9.16, the most followed narrative sees fair value at $26.00, using a detailed, assumption heavy view of Ocular Therapeutix’s future.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6–12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Curious what has to happen for that valuation to make sense? Revenue growth, margins and share count all carry big assumptions that reshape the earnings profile and implied multiple.

Result: Fair Value of $26.00 (UNDERVALUED)

However, this hinges heavily on AXPAXLI, so any clinical or regulatory setback, or pressure on pricing versus existing wet AMD therapies, could quickly challenge that upbeat narrative.

Another View on Value

The popular narrative leans on future growth to argue Ocular Therapeutix is undervalued at US$9.16 versus a US$26.00 fair value. Yet on today’s numbers, the stock trades on a P/S ratio of 38.5x compared with 4.8x for the US Pharmaceuticals industry, peers at 1.6x, and a fair ratio of just 0.1x, which signals meaningful valuation risk if expectations reset.

Next Steps

With sentiment clearly split between risk and reward, this is a moment to review the numbers yourself and decide quickly where you stand, starting with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better match your goals, risk comfort and income needs across the market.

• Target potential mispricing by checking 44 high quality undervalued stocks that combine quality fundamentals with appealing valuations.
• Strengthen your income stream by reviewing 13 dividend fortresses built around higher yielding companies.
• Dial down risk by focusing on 69 resilient stocks with low risk scores that score well on resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.